Eledon Pharmaceuticals, Inc. (ELDN)

Eledon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	19.64	18.61	12.69	13.1	13.43	7.35
Research & Development	68.26	51.96	30.31	26.68	23.44	5.93
Operating Expenses	87.9	70.58	43	39.78	36.87	13.28
Operating Income	-87.9	-70.58	-43	-39.78	-36.87	-13.28
Other Non Operating Income (Expenses)	102.98	34.82	-73.54	0.46	0.01	0.08
EBT Excluding Unusual Items	15.07	-35.75	-116.54	-39.32	-36.86	-13.2
Merger & Restructuring Charges	-	-	-	-	-	-5.18
Impairment of Goodwill	-	-	-	-48.65	-	-
Other Unusual Items	-	-	-	-	-	-4.83
Pretax Income	15.07	-35.75	-116.54	-87.97	-36.86	-23.22
Income Tax Expense	0.43	0.43	-	-	-2.35	-0.4
Net Income	14.64	-36.18	-116.54	-87.97	-34.51	-22.81
Net Income to Common	14.64	-36.18	-116.54	-87.97	-34.51	-22.81
Shares Outstanding (Basic)	69	49	25	14	15	1
Shares Outstanding (Diluted)	69	49	25	14	15	1
Shares Change (YoY)	108.60%	97.18%	72.34%	-3.61%	921.03%	121.42%
EPS (Basic)	0.21	-0.75	-4.73	-6.16	-2.33	-15.72
EPS (Diluted)	0.21	-0.75	-4.73	-6.16	-2.33	-15.72
Free Cash Flow	-64.53	-47.27	-39.53	-28.42	-28.91	-15.21
Free Cash Flow Per Share	-0.94	-0.97	-1.61	-1.99	-1.95	-10.48
EBITDA	-	-	-	-	-36.86	-13.28
D&A For EBITDA	-	-	-	-	0.01	0.01
EBIT	-87.9	-70.58	-43	-39.78	-36.87	-13.28

Updated Aug 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q